145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 145,045 shares of the company’s stock, valued at approximately $3,731,000. Great Lakes Advisors LLC owned about 0.09% of Denali Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DNLI. BlackRock Inc. purchased a new stake in Denali Therapeutics in the second quarter worth $360,759,000. Norges Bank purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at $84,525,000. ADAR1 Capital Management LLC lifted its position in shares of Denali Therapeutics by 3,490.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock valued at $35,932,000 after buying an additional 1,819,339 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock worth $63,329,000 after acquiring an additional 1,672,098 shares during the period. Finally, Temasek Holdings Private Ltd grew its stake in shares of Denali Therapeutics by 30.9% during the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after acquiring an additional 1,657,142 shares during the period. Institutional investors own 92.92% of the company’s stock.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.70% of the stock is owned by company insiders.

Denali Therapeutics Price Performance

DNLI stock opened at $24.95 on Friday. The firm has a 50 day moving average of $24.39 and a 200-day moving average of $21.58. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 12 month low of $12.58 and a 12 month high of $27.30. The firm has a market capitalization of $3.99 billion, a P/E ratio of -8.79 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the previous year, the business earned ($0.72) earnings per share. As a group, sell-side analysts predict that Denali Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Wedbush reiterated an “outperform” rating and issued a $26.00 target price on shares of Denali Therapeutics in a research note on Monday, July 13th. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a research report on Friday, August 7th. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Denali Therapeutics in a research note on Monday, May 11th. Finally, UBS Group raised their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.92.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.